Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MC4R | P32245 | 1/20 | 0.66 |
| ▸ | CHKA | P35790 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | NCF1 | P14598 | 1/20 | 0.59 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612427 | 0.93 | CHKA (0.75) | LMNAMC4RCHKACA2NCF1 | |
| SCHEMBL8117468 | 0.89 | MAPT (0.67) | MAPTKDM4E | |
| SCHEMBL16121669 | 0.88 | CHKA (0.84) | LMNACHKACA2NCF1PRMT6 | |
| SCHEMBL16226139 | 0.84 | POLB (0.61) | LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL13869588 | 0.84 | ALDH1A1 (0.69) | ALDH1A1MAPTKDM4E | |
| SCHEMBL10686392 | 0.84 | SIGMAR1 (0.60) | MAPTKDM4E | |
| SCHEMBL22642436 | 0.83 | MAPT (0.61) | MAPTKDM4E | |
| SCHEMBL5745400 | 0.82 | KCNJ1 (0.61) | MC4RALDH1A1 | |
| SCHEMBL9096825 | 0.82 | MAPT (0.56) | MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL10502749 | 0.82 | SIGMAR1 (0.59) | MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101090723-A | Piperazine urea derivatives for the treatment of endometriosis | SCHERING AG (DE) | 2007-12-19 | — | — | CN | claimed |
| EP-3512852-B1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-26 | — | — | EP | disclosed |
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3285583-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3241554-B1 | QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | AGIOS PHARMACEUTICALS INC (US) | 2020-01-29 | — | — | EP | disclosed |
| US-10479790-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2019-11-19 | — | — | US | disclosed |
| WO-2019180207-A1 | TRAF 6 INHIBITORS | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2019-09-26 | — | — | WO | disclosed |
| US-10174028-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10035799-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2018-07-31 | — | — | US | disclosed |
| WO-2018136661-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-07-26 | — | — | WO | disclosed |
| CN-101090723-A | Piperazine urea derivatives for the treatment of endometriosis | SCHERING AG (DE) | 2007-12-19 | — | — | CN | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| CN-1938029-A | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma | UNIV PITTSBURGH (DE) | 2007-03-28 | — | — | CN | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| CN-1838957-A | Chemokine inhibiting piperazine derivatives and their use to treat myocarditis | SCHERING AKTIEGESELLSCHAFT (DE) | 2006-09-27 | — | — | CN | disclosed |
| EP-1545528-A4 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1545528-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004022712-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174028-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | LMNA 2697/4885MC4R 1447/4885CHKA 1773/4885 |
| US-10035799-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | LMNA 4344/4885MC4R 1110/4885CHKA 2807/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | LMNA 4087/4885MC4R 465/4885CHKA 2989/4885 |
| US-10479790-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | LMNA 4344/4885MC4R 1110/4885CHKA 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.